The trials main goal was to evaluate the percentage of patients showing complete resolution of MASH without liver fibrosis worsening after 52 weeks of treatment
Most adverse events were mild to moderate gastrointestinal events, primarily occurring during the dose-escalation period
These observations have been hypothesized to be due to a higher medication exposure among women, i.e., increased plasma concentration of the treatment due to their lower mean body weight
NICE guideline CG189 and Public Health guideline PH53 recommend multicomponent interventions including dietary modification (aiming for 600 kcal/day deficit), increased physical activity, and behavioural strategies
Glutathione, when effective at all, may take 4-6 months to show results that often fade after discontinuation
This article examines the evidence, mechanisms, and practical management strategies for headaches associated with weight loss injections